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Abstract: The aim of this study was to identify respiratory viruses circulating amongst elite 
racehorses in a training yard by serological testing of serial samples and to determine their impact 
on health status and ability to race. A six-month longitudinal study was conducted in 30 
Thoroughbred racehorses (21 two-year-olds, five three-year-olds and four four-year-olds) during 
the Flat racing season. Sera were tested for the presence of antibodies against equine herpesvirus 1 
and 4 (EHV-1 and EHV-4) and equine rhinitis viruses A and B (ERAV and ERBV) by complement 
fixation (CF) and equine arteritis virus (EAV) by ELISA. Antibodies against equine influenza (EI) 
were measured by haemagglutination inhibition (HI). Only ERAV was circulating in the yard 
throughout the six-month study period. Seroconversion to ERAV frequently correlated with clinical 
respiratory disease and was significantly associated with subsequent failure to race (p = 0.0009). 
Over 55% of the two-year-olds in the study seroconverted to ERAV in May and June. In contrast, 
only one seroconversion to ERAV was observed in the older horses. They remained free of any signs 
of respiratory disease and raced successfully throughout the study period. The importance of ERAV 
as a contributory factor in the interruption of training programmes for young horses may be 
underestimated. 
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1. Introduction 
Equine respiratory infection together with lameness are the most common reasons for loss of 
training days and inability to race [1]. The main viruses associated with respiratory disease and loss 
of performance in racehorses are equine influenza virus (EI), equine herpesvirus 1 and 4 (EHV-1 and 
EHV-4) and equine rhinitis viruses A and B (ERAV and ERBV). 
EI is a highly contagious virus and outbreaks of influenza may necessitate the cancellation of 
race meetings and other equestrian events [2]. However, in 1981, mandatory vaccination against EI 
was introduced for Thoroughbred racehorsesin Ireland and since then, no race meetings have been 
cancelled due to EI. However, outbreaks continue to occur in vaccinated horses, and young 
racehorses are particularly susceptible [3–5]. The return to athletic normality can be prolonged by 
damage to the mucociliary clearance mechanism and secondary bacterial infections [6]. 
EHV-1 and -4 circulate in horse populations worldwide and are associated with respiratory 
disease in horses, immunosuppression, reduced performance, abortion and occasionally, 
neurological disease [7–9]. Although there is no mandatory vaccination programme for EHV-1 and -
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4 in Ireland, some trainers vaccinate their horses in an effort to reduce the virus challenge in their 
yards. 
ERAV and ERBV have also been identified worldwide in both healthy horses and horses with 
clinical respiratory signs [10–16]. A seroprevalence of 57% and 71% for ERAV and ERBV was 
recorded for Thoroughbred yearlings in Kentucky [17] and seroconversion to ERAV is common 
among young horses on entry to training yards [18–20]. Furthermore, ERBV was isolated in 30% of 
the horses with acute respiratory diseases in a Canadian survey [10]. 
There is a need for serological surveys to identify the viruses associated with economic loss in 
the racing industry. Longitudinal surveillance studies contribute to our understanding of the 
epidemiology of equine respiratory diseases in different countries and in different populations of 
horses. The aim of this serological study was to identify respiratory viruses circulating amongst elite 
racehorses of different ages in a training yard in Ireland and to determine their impact on health 
status and ability to race. 
2. Materials and Methods 
A six-month longitudinal study was conducted in 30 Thoroughbred racehorses during the Flat 
season. All the horses originated from the same stud farm and were in training with the same trainer. 
There were three different age groups of horses; the main group, i.e., 21 (70%) horses were two years 
of age, five (17%) of the horses were three years old and four (13%) were four years old. The two-
year-old horses were in training for their first season. All the horses had been vaccinated against EI 
and EHV1 prior to entering the training yard. 
At the request of the owner, whole blood samples were collected by the veterinary surgeon at 
monthly intervals from April to September. These were for routine serological screening and 
archiving as the “acute” samples for the testing of paired sera (“acute” and “convalescent”) in the 
event of an outbreak of respiratory disease. Additional blood samples were collected from horses 
with respiratory disease in mid-May. 
Similarly to previous longitudinal studies of Thoroughbred racehorses in training [21–23], sera 
were tested for presence of antibodies against ERAV, ERBV, EHV-1 and EHV-4 using the 
Complement fixation (CF) test. The test was performed as described by Thomson et al. [24], using 
guinea pig complement and sensitized sheep erythrocytes. Serial twofold dilutions of sera from 1:5 
to 1:640 were tested. Sera were tested for antibodies against EI H7N7 and H3N8 viruses using the 
Haemagglutination Inhibition (HI) test. The sera were pretreated with potassium periodate, 
inactivated for 30 min at 56 °C ( ± 1 °C) and tested as described previously [25]. Seroconversion was 
defined as a 4-fold or higher rise in CF or HI antibody titers. Sera were tested for the presence of 
antibodies against equine arteritis virus (EAV) by indirect ELISA (ID Screen® Equine Viral Arteritis 
Indirect -Grabels, France). 
A Chi-squared test was used to test the association of seroconversion with subsequent failure to 
race. The data was summarised in 2 × 2 contingency tables and an analysis was conducted in the R 
statistical software package version 3.5.1. The statistical significance was set at α = 0.05. 
3. Results 
The numbers of samples taken during the study period were distributed over the age groups as 
follows: 154 (71%) were from two-year-old horses, 35 (16%) were from the three-year-old horses and 
28 (13%) of the samples were collected from four-year-old horses. 
The two-year-old horses entered the training yard where the older horses resided in the 
beginning of April. At the time of first sampling, all the horses tested by HI (n = 26) had antibody 
titres against EI that were consistent with vaccination. All the horses had undetectable or low 
antibody titres (≤ 20) against EHV1 and 4. During the study period, five horses seroconverted to EI 
and 12 to EHV-1 and/or EHV-4 in response to vaccination. The remaining horses were not vaccinated 
against these viruses during the study period and no other seroconversions to EI, EHV-1 or EHV-4 
were detected. All the horses were seronegative for EAV throughout the study period. Thus, there 
was no serological evidence of natural exposure to these viruses during the study period. 
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With the exception of two of the two-year-old horses (antibody titres of 80 and 40) all the horses 
had undetectable or low antibody titres (≤ 20) against ERAV at the time of first sampling in April. 
This was also true for ERBV, with the exception of one two-year-old with an antibody titre of 40. The 
first seroconversion to ERAV was observed at the second sampling occasion in the beginning of May. 
One seronegative two-year-old colt had mounted a significant antibody response to ERAV (0 to 160) 
within four weeks of arriving in the training yard. He did not exhibit clinical respiratory signs but 
was described by the trainer as very slow at work. Within the following two weeks, clinical signs, 
including inappetence, dullness, nasal discharge, limb oedema, enlarged submandibular lymph 
nodes and occasional coughing, were observed in seven of the in-contact two-year-old horses. They 
were returned to the stud farm of origin to recuperate where blood samples were collected for 
serological testing. Four of the horses seroconverted to ERAV during the first two weeks in May, two 
were seropositive with stable titres, and one seroconverted at a later time point. 
The ERAV serological results are summarized in Figure 1. Four additional seroconversions in 
two-year-old horses were identified by the end of May. Three of these horses had acute respiratory 
disease and were moved back to the stud farm. The fourth horse was subclinically infected and 
remained in training but was slow at work. By the end of June, four new seroconversions to ERAV 
were detected but only one horse had clinical respiratory signs and was returned home. One 
subclinically infected horse had previously seroconverted in early May. 
 
Figure 1. The number of horses that seroconverted to equine rhinitis A virus (ERAV) each month 
during the study period (April to September). 
The number of seroconversions to ERAV decreased with time, with two in July, one of which 
was a horse that had previously seroconverted in the first week of May. One horse seroconverted in 
August and one in September, which had seroconverted previously in May. In contrast to the initial 
exposure to virus, these seroconversions in autumn were not associated with clinical respiratory signs 
or loss of performance. 
No seroconversions to ERAV or ERBV and no clinical respiratory signs were observed in the 
three-year-old horses during the study period. One four-year-old horse seroconverted to ERAV at 
the end of May, but no clinical signs were observed and he won a race five days before the 
seropositive blood sample was collected. 
In total, 18 seroconversions to ERAV were detected during the study period and 17 of them were 
in two-year-old horses. The majority, i.e. 13 (72%) of the seroconversions occurred in May and June. 
Only one of the two-year-old horses raced in May prior to being sent back to the stud farm to recover 
from respiratory disease. The two-year-old horses did not start racing after the respiratory episode 
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meetings was strikingly low when compared to the other two age groups. In total, during the study 
period, the five three-year-old horses raced 20 times and were placed first, second or third 12 times. 
The four older horses raced 12 times with six places. Only six of the 21 two-year-old horses raced. 
However, from 18 starts, they were placed 11 times. There was a significant association between 
seroconversion to ERAV and subsequent failure to race (p = 0.009). 
 
Figure 2. The percentage of horses that raced per month during the study period. The percentage of 
(a) two-year-old horses (b) three-year-old horses and (c) four-year-old horses that raced is shown. 
The time from seroconversion to ERAV until the titers decreased to insignificant levels ranged 
from three weeks to five months, with a median value of two months and a mean value of 2.3 months. 
An association was observed between the antibody level and the rate of decline to original level. 
Only one seroconversion to ERBV was observed in this study, a two-year-old horse 
seroconverted in June without any associated clinical respiratory signs. 
4. Discussion 
In this study, exposure to ERAV, as determined by serological testing, was associated with 
respiratory disease, loss of training days and failure to race in young racehorses. Monthly screening 
indicated that the majority of two-year-old horses were exposed to ERAV during the three months 
after entering the yard. The clinical signs that resulted in an interruption to training were primarily 
observed after the horses had been in the yard for several weeks and were being prepared for their 
first race. The susceptibility of young horses to rhinitis virus infection when moved to a new 
environment and starting to comingle with other horses has been reported previously [26,27]. In a 
seven-year serological study of racehorses in Japan, 69% of horses that seroconverted to ERAV were 
two years of age [16] and Black et al. [18] reported that 43% of horses seroconverted to ERAV within 
7 months of entering a training stable in Australia. A previous study in a training yard in Ireland 
indicated that ERAV infection was largely confined to two-year-old horses and was most prevalent 
in late winter and spring [19]. However, we believe that this is the first investigation of the association 
between ERAV infection with interrupted training and failure to race. Over 55% of the two-year-olds 
in the study seroconverted to ERAV in May and June and none of them raced at that time. In fact, 
only 29% of the two-year-olds raced in their first season. 
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The results of this study suggest that the importance of ERAV in the interruption of training 
programmes for young horses may be underestimated. Acute febrile respiratory disease following 
ERAV infection has been reported previously [11,15,28,29]. In an experimental study, ERAV-
inoculated ponies developed respiratory tract disease characterized by pyrexia, nasal discharge, 
adventitious lung sounds, and enlarged mandibular lymph nodes, which corresponded with an 
increase in antibody titres against the virus [29]. The clinical signs observed during this study were 
associated with the seroconversions and there was no evidence of other viral infections. ERAV may 
have been the primary cause of the respiratory disease and subsequent training loss, but it is more 
likely that the virus was a contributory factor in a multifactorial disorder. The serology tests used in 
this study are sensitive and specific, but it is possible that other less common viruses, such as 
adenovirus and coronavirus, or even as-yet unidentified equine viruses, may have played a role. 
Previous studies have demonstrated the complexity of poor performance syndrome in Thoroughbred 
racehorses and that bacteria are more common and may be aetiologically more important than 
viruses [21–23]. Unfortunately, the possible role of bacterial infection as a cofactor was not 
investigated in this study and the statistically significant association of ERAV with failure to race 
during the study period does not conclusively demonstrate causation. However, it is essential to 
determine which infectious agents are prevalent in populations that suffer interruption to training as 
a first step in assessing their true impact. 
Lack of previous exposure to ERAV and stress associated with the change of environment and 
intensive training may have contributed to disease susceptibility. In contrast to the two-year-old 
horses, no seroconversions to ERAV were observed in the three-year-old horses—they remained free 
of any signs of respiratory disease and raced successfully throughout the study period. The 
seroconversion to ERAV in the four-year-old horse and the reinfection of two of the younger horses 
were not associated with clinical signs or reduced performance. Experimental studies have indicated 
that ERAV infection stimulated a protective response and that reinfection is asymptomatic [29]. 
The serology results indicate that ERAV was circulating in the yard throughout the six month 
study period. The dynamics of ERAV infection in horse populations are poorly understood but virus 
persists in horses even in the presence of high levels of antibodies [26,28]. ERAV can be isolated from 
the blood for a few days post infection and from the nasopharynx and faeces for up to a month [28]. 
Studies in the USA, Ireland and Australia detected ERAV in post-race urine samples at frequencies 
of 17%, 29% and 23%, respectively, which led to a suggestion that the persistent presence of ERAV in 
urine may contribute to its maintenance in training yards [17,30,31]. ERBV was not detected in urine 
[17,30]. During this study period, only one horse seroconverted to ERBV. This was consistent with an 
earlier study in Ireland in which ERAV was found to be more commonly detected than ERBV [30]. 
Co-circulation of ERAV and ERBV was also reported previously [30]. 
The low seroprevalence of ERAV and ERBV detected in the older horses at the beginning of this 
study may be due to the use of the CF test rather than the virus neutralization test (VNT) favored by 
some investigators [13,18,32]. The CF test is useful for the diagnosis of acute infections, as positive 
CF titres are often an indication of immunoglobulin M (IgM) antibodies or very high levels of IgG. 
Neutralizing antibodies which are mainly IgG persist for many years and the VNT is the test of choice 
for seroprevalence studies [33]. Burrows (1969) [34] reported that 59% of mares had neutralizing 
antibody against ERAV, in contrast to 10% of foals and yearlings, and suggested that most infection 
occurs during the period of training and racing. The relationship between neutralizing antibodies 
and clinical protection has been established Diaz-Mendez et al. [29]. It is likely that the older horses 
in this study that were seronegative by the CF test were exposed to ERAV in their first year of training 
and had neutralizing antibodies at the start of the study that were sufficient to protect them from 
infection and subsequent seroconversion, as measured by the CF test. However, this hypothesis 
remains unproven and it is also possible that although they were in the same yard as the two-year-
old horses, they may not have been exposed to the virus. In this study, the CF antibodies declined to 
the original levels within months, confirming that they are not persistent and thus, a useful indicator 
of recent exposure to virus. As no relationship between CF antibodies and protection has been 
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proposed, an investigation of an outbreak of ERAV including the measurement of neutralizing 
antibodies would give useful insight into protection. 
In summary, this study demonstrates that routine serological monitoring of young racehorses 
by CF test revealed that ERAV is potentially an important contributor to training loss in young 
racehorses and merits further investigation with larger study populations and a more comprehensive 
testing regime. Unfortunately, only five nasopharyngeal samples were collected during this study, 
and all were negative for EHV1, EHV4, EI, EAV, ERAV and ERAB by real time PCR (data not shown). 
None of the nasal swabs were collected at the optimal time for detection of ERAV, which 
experimental infections suggest is from one to 12 days post-infection [31]. Further investigations in 
which samples are methodically collected for virus detection, serology and bacteriological 
investigation would be beneficial in elucidating the role of ERAV and other pathogens in the poor 
performance in young racehorses. However, all such field studies are dependent on the cooperation 
of the owner and the availability of horses. 
ERAV is not contained in any of the vaccines that are currently available. As no clinical signs 
were attributable to reinfection, it is likely that immunization would be effective. The results of this 
study suggest that strategic vaccination of young horses against this virus could reduce economic 
loss due to respiratory disease and interruption of training schedules. 
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